Evaluation and Management of Elevated Ferritin
When you encounter elevated ferritin, immediately measure transferrin saturation (TS) alongside ferritin, because iron overload is NOT the most common cause of hyperferritinemia in the general population 1, 2.
Initial Diagnostic Approach
Step 1: Rule Out Common Non-Iron Overload Causes
Over 90% of elevated ferritin cases are due to conditions other than iron overload 2. Before pursuing genetic testing or advanced workup, systematically exclude:
- Inflammatory conditions: Check C-reactive protein (CRP)
- Cell necrosis: Check AST, ALT, and creatine kinase (CK)
- Liver disease: Alcoholic liver disease, chronic hepatitis B/C, NAFLD 1
- Metabolic syndrome: Assess blood pressure, BMI, cholesterol, triglycerides, glucose 2
- Malignancy: Check ESR, consider CT scan if clinically indicated 2
- Chronic alcohol consumption: Direct history
- Lymphomas and chronic inflammatory conditions 1
Critical caveat: Ferritin is an acute-phase reactant that rises with inflammation independent of iron stores 1.
Step 2: Measure Transferrin Saturation
If TS ≥45% AND ferritin is elevated, proceed to HFE genetic testing 1. This combination significantly increases the likelihood of hereditary hemochromatosis (HH).
If TS is normal (<45%) but ferritin is elevated, iron overload is unlikely and you should focus on the inflammatory/metabolic causes listed above 1.
Genetic Testing Strategy
When to Order HFE Testing
Order HFE mutation analysis (C282Y and H63D) when 1:
- TS ≥45% with any ferritin elevation
- Suggestive symptoms: unexplained liver disease, chondrocalcinosis, type 1 diabetes, arthralgia, cardiomyopathy
- First-degree relative with confirmed hemochromatosis
- Elevated liver enzymes with hyperferritinemia
Interpreting Genetic Results
C282Y homozygotes: Diagnosis of HFE hemochromatosis is confirmed if iron stores are elevated. Proceed to treatment planning 2.
C282Y/H63D compound heterozygotes or H63D homozygotes: First investigate other causes of hyperferritinemia before attributing to genetics. These genotypes have low penetrance and rarely cause significant iron overload alone 2, 3.
Risk Stratification for Cirrhosis
Ferritin <1000 μg/L: Accurately predicts absence of cirrhosis 1.
Ferritin >1000 μg/L with elevated ALT/AST AND platelet count <200: Predicts cirrhosis in 80% of C282Y homozygotes 1.
When to Consider Liver Biopsy
Offer liver biopsy to C282Y homozygotes with 2:
- Ferritin >1000 μg/L
- Elevated AST or ALT
- Hepatomegaly
- Age >40 years
Liver biopsy is no longer necessary to diagnose hemochromatosis in C282Y homozygotes with confirmed iron overload 2.
Advanced Imaging
MRI for hepatic iron quantification should be used when 3:
- Unclear cause of hyperferritinemia persists after initial workup
- Biochemical iron overload is present (elevated TS and ferritin)
- Liver biopsy shows positive iron staining but diagnosis remains uncertain
- Need to quantify hepatic iron concentration and assess extrahepatic organ involvement
Recent evidence shows that TS >60% or TS <60% with ferritin >963 μg/L correctly identifies 95% of patients with severe hepatic iron overload (>7 mg/g), potentially reducing unnecessary MRI by over 50% 4.
Treatment Decisions
Confirmed HFE Hemochromatosis (C282Y Homozygotes)
Initiate therapeutic phlebotomy for 1:
- Any evidence of liver disease or end-organ manifestations
- Asymptomatic patients with elevated ferritin (even moderately elevated, e.g., 800 μg/L) with normal liver tests
Rationale: Treatment is safe, inexpensive, and prevents progression to cirrhosis and hepatocellular carcinoma. There are no reliable indicators of who will develop complications, so prophylactic phlebotomy is favored 1.
Phlebotomy Protocol
- Remove 1 unit of blood (200-250 mg iron) once or twice weekly 1
- Check hemoglobin/hematocrit before each session; avoid reducing to <80% of baseline 1
- Monitor ferritin every 10-12 phlebotomies (approximately 3 months) 1
- Target ferritin: 50-100 μg/L (not iron deficiency) 1
- Maintenance phlebotomy frequency varies: monthly to 1-2 units per year depending on reaccumulation rate 1
Outcomes of Early Treatment
When treatment begins before cirrhosis and diabetes develop 1:
- Improved survival
- Reversal of hepatic fibrosis in ~30% of cases
- Improved cardiac function and diabetes control
- Normalization of liver enzymes
- Elimination of HCC risk (HCC is exceptionally rare in noncirrhotic HH) 1
Critical warning: Once cirrhosis develops, continue HCC screening indefinitely even after successful phlebotomy, as HCC accounts for 30% of HH-related deaths 1.
Referral Criteria
Refer to gastroenterology, hematology, or iron overload specialist when 5:
- Ferritin >1000 μg/L
- Cause of elevated ferritin remains unclear after initial workup
- Confirmed hemochromatosis requiring treatment coordination
Common Pitfalls to Avoid
- Don't assume elevated ferritin equals iron overload: Check TS first 1
- Don't order HFE testing without checking TS: Wastes resources and creates confusion 1
- Don't ignore elevated ferritin in NAFLD patients: While common, ferritin >300 μg/L (men) or >200 μg/L (women) with elevated TS still warrants HFE testing 6
- Don't stop HCC surveillance after phlebotomy in cirrhotic patients: Risk persists 1
- Don't pursue iron overload workup when ferritin is elevated but TS is normal: Focus on inflammatory/metabolic causes 1